Liu Yong-Dong, Zhang Gui-Feng, Li Jing-Jing, Chen Jing, Wang Yin-Jue, Ding Hong, Su Zhi-Guo
National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beiertiao 1, Zhongguancun, Beijing 100080, People's Republic of China.
Biotechnol Appl Biochem. 2007 Dec;48(Pt 4):189-98. doi: 10.1042/BA20070047.
Dilution refolding of recombinant consensus IFN (interferon) from inclusion bodies suffers from low yield. A stable intermediate was found to mix with the correct product and to have an antiviral activity of less than 10% of the latter. This intermediate would form precipitates upon removal of the precipitation inhibitor arginine. Compared with the native protein, the intermediate moved more slowly on non-reducing SDS/PAGE. The CD and fluorescence spectra indicated that it had formed a native-like structure, but had only one disulfide bond: Cys(29)-Cys(139). Further evidence showed that the formation of Cys(29)-Cys(139) is specific and very likely to happen, even in the presence of a high concentration of reducing agent, whereas pairing of the other disulfide (Cys(1)-Cys(99)) needed a stronger oxidative condition. It competed with intermolecular disulfide bonding to form covalent oligomers. On the basis of this discovery, a two-stage refolding step strategy was designed that employed a modified dilution refolding step followed by a dialysis refolding step. The first stage used a high concentration of reducing agent together with the precipitation inhibitor arginine. The purpose was to hinder any reaction through Cys(1) or Cys(99) but allow the intramolecular disulfide bonding of Cys(29)-Cys(139). The second stage was a dialysis step that gradually increased the oxidative agent concentration and simultaneously decreased the arginine concentration. The refolding yield was increased from 35 to 82%, while the mass recovery was increased from 60 to 96%. Moreover, this strategy could suppress precipitation even after arginine was completely removed.
从包涵体中对重组共有干扰素(IFN)进行稀释复性,收率较低。发现一种稳定的中间体与正确产物混合,其抗病毒活性不到后者的10%。去除沉淀抑制剂精氨酸后,这种中间体会形成沉淀。与天然蛋白相比,该中间体在非还原SDS/PAGE上迁移较慢。圆二色光谱和荧光光谱表明它形成了类似天然的结构,但只有一个二硫键:Cys(29)-Cys(139)。进一步的证据表明,即使在高浓度还原剂存在的情况下,Cys(29)-Cys(139)的形成也是特异性的,而且很可能发生,而另一个二硫键(Cys(1)-Cys(99))的配对需要更强的氧化条件。它与分子间二硫键形成竞争,以形成共价寡聚物。基于这一发现,设计了一种两步复性策略,包括一个改良的稀释复性步骤,随后是一个透析复性步骤。第一阶段使用高浓度还原剂和沉淀抑制剂精氨酸。目的是阻碍通过Cys(1)或Cys(99)的任何反应,但允许Cys(29)-Cys(139)的分子内二硫键形成。第二阶段是透析步骤,逐渐增加氧化剂浓度,同时降低精氨酸浓度。复性收率从35%提高到82%,而质量回收率从60%提高到96%。此外,即使精氨酸完全去除后,该策略也能抑制沉淀。